Neuland Laboratories Ltd.
Snapshot View

2160.15 +47.50 ▲2.3%

23 July 2021, 04:00:00 P.M.
Volume: 1,671

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.neulandlabs.com
Financial Indicators
Market Cap 2,802.18 Cr.
Earnings per share (EPS) 62.85 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 34.75 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 612.28 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.57 Calculated using Price: 2,184.10
Dividend Yield 0.23 Period Ending 2021-03
No. of Shares Subscribed 1.28 Cr. 12,829,889 Shares
FaceValue 10
Company Profile

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

  • Anti -Asthmatics
  • Fluoroquinolones
  • Cardiovascular
  • CNS
  • Corticosteroids
  • Anti-Ulcerant
  • Anti-Fungal
  • Anti-Parkinsons
  • Anti-Alzheimers

Achievements/ recognition:

  • Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
  • USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
  • Received cGMP clearance for both facilities from TGA, Australia in 2004.
  • Certificate of suitability for product itraconazole in 2006.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.25%
1 Week
-1.53%
1 Month
+7.45%
3 Month
-13.93%
6 Month
+59.59%
1 Year
+219.43%
2 Year
+328.09%
5 Year
+125.43%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 15.92 24.14 11.24 15.64 22.34 5.02 3.48 2.30 10.79
Return on Capital Employed (%) 15.58 18.99 15.75 18.57 15.98 4.07 3.99 7.85 12.81
Return on Assets (%) 3.26 5.89 3.20 5.23 6.65 1.23 1.49 1.37 6.31

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 100 124 161 187 546 558 699 710 786
Non Curr. Liab. 62 52 55 69 54 146 104 163 170
Curr. Liab. 263 307 295 268 286 367 327 358 369
Minority Int. 0 0 0
Equity & Liab. 425 483 512 524 886 1,071 1,130 1,231 1,325
Non Curr. Assets 198 196 196 210 511 624 677 716 775
Curr. Assets 227 288 316 314 375 447 453 515 550
Misc. Exp. not W/O
Total Assets 425 483 512 524 886 1,071 1,130 1,231 1,325

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 461 466 469 510 579 527 667 763 937
Other Income 4 3 1 2 1 5 3 4 16
Total Income 465 469 470 512 580 532 670 767 953
Total Expenditure -403 -395 -403 -430 -473 -477 -608 -661 -790
PBIDT 62 74 67 82 108 55 62 106 163
Interest -31 -25 -27 -24 -21 -19 -16 -22 -18
Depreciation -15 -15 -15 -16 -19 -22 -26 -31 -40
Taxation -2 -8 -9 -15 -20 -2 -4 -37 -25
Exceptional Items
PAT 14 27 16 27 47 12 16 16 81

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 26 49 13 45 39 11 70 57 189
Cash Fr. Inv. -7 -10 -14 -20 -42 -116 -77 -49 -84
Cash Fr. Finan. -20 -39 1 -24 0 105 12 -5 -114
Net Change -1 0 0 1 -4 0 5 3 -9
Cash & Cash Eqvt 1 1 1 2 3 3 8 11 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 35.90 35.86 35.86 36.20 36.27 36.25 36.25 36.22 36.22
Public 64.10 64.14 64.14 63.80 63.73 63.75 63.75 63.78 63.78
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 4.34 4.35 4.35 4.31 4.30 4.30 4.30 4.30 4.30

Announcements View Details

Fri, 16 Jul 2021
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter Ended June 30 2021
NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2021 inter alia to consider and approve the Unaudited Financial Results for the quarter ended June 30 2021.
Mon, 12 Jul 2021
Shareholding for the Period Ended June 30 2021
Neuland Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Thu, 08 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%